GSK’s (GSK) Neutral Rating Reaffirmed at UBS Group

UBS Group reiterated their neutral rating on shares of GSK (LON:GSK) in a research note released on Friday morning, Marketbeat Ratings reports. They currently have a GBX 1,940 price target on the stock.

Other analysts have also recently issued reports about the company. Shore Capital restated a “buy” rating on shares of GSK in a research report on Thursday, January 8th. Berenberg Bank raised their price target on GSK from GBX 1,600 to GBX 1,660 and gave the company a “hold” rating in a report on Monday, November 24th. Jefferies Financial Group reaffirmed a “buy” rating and issued a GBX 2,100 price objective on shares of GSK in a report on Wednesday, January 7th. JPMorgan Chase & Co. reiterated an “underweight” rating on shares of GSK in a research report on Wednesday, January 7th. Finally, Deutsche Bank Aktiengesellschaft boosted their price target on shares of GSK from GBX 1,600 to GBX 1,675 and gave the stock a “hold” rating in a research report on Thursday, January 15th. Two investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, GSK presently has a consensus rating of “Hold” and a consensus target price of GBX 1,829.17.

GSK Trading Up 0.2%

Shares of LON:GSK opened at GBX 1,807.64 on Friday. The company has a quick ratio of 0.73, a current ratio of 0.81 and a debt-to-equity ratio of 114.64. The company’s 50-day moving average price is GBX 1,817.89 and its 200 day moving average price is GBX 1,630.28. The company has a market cap of £72.92 billion, a PE ratio of 13.59, a P/E/G ratio of 1.24 and a beta of 0.31. GSK has a fifty-two week low of GBX 1,242.50 and a fifty-two week high of GBX 1,909.73.

GSK (LON:GSK) last announced its quarterly earnings results on Wednesday, October 29th. The company reported GBX 55 EPS for the quarter. GSK had a net margin of 8.02% and a return on equity of 18.08%. Sell-side analysts anticipate that GSK will post 175.980975 earnings per share for the current year.

Insider Transactions at GSK

In other GSK news, insider Jonathan Symonds acquired 1,650 shares of GSK stock in a transaction dated Monday, December 22nd. The stock was bought at an average price of GBX 1,810 per share, for a total transaction of £29,865. Also, insider Wendy Becker acquired 441 shares of the stock in a transaction dated Friday, December 19th. The stock was acquired at an average cost of GBX 1,809 per share, for a total transaction of £7,977.69. 0.20% of the stock is currently owned by corporate insiders.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.